Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells

被引:57
作者
Navarra, Michele [1 ,6 ]
Celano, Marilena [2 ]
Maiuolo, Jessica [2 ]
Schenone, Silvia [3 ]
Botta, Maurizio [4 ]
Angelucci, Adriano [5 ]
Bramanti, Placido [6 ]
Russo, Diego [2 ]
机构
[1] Univ Messina, Pharmacobiol Dept, I-98100 Messina, Italy
[2] Magna Graecia Univ Catanzaro, Dept Pharmacobiol Sci, I-88100 Catanzaro, Italy
[3] Univ Genoa, Dept Pharmaceut Sci, I-16132 Genoa, Italy
[4] Univ Siena, Pharmacochem Technol Dept, I-53100 Siena, Italy
[5] Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy
[6] IRCCS Ctr Neurolesi Bonino Pulejo, I-98124 Messina, Italy
来源
BMC CANCER | 2010年 / 10卷
关键词
CANCER-THERAPY; IN-VITRO; IMATINIB MESYLATE; TYROSINE KINASES; CARCINOMA-CELLS; FAMILY KINASES; C-SRC; EXPRESSION; TARGETS; TUMORS;
D O I
10.1186/1471-2407-10-602
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Neuroblastoma (NB) is the second most common solid malignancy of childhood that usually undergoes rapid progression with a poor prognosis upon metastasis. The Src-family tyrosine kinases (SFKs) are a group of proteins involved in cancer development and invasiveness that seem to play an important role in the NB carcinogenesis. Methods: To determine cell proliferation, the growth rate was evaluated by both MTT test and cells counted. Analysis of DNA content was performed for the evaluation of the cell cycle and apoptosis. To characterize the mechanisms underlying the antiproliferative effects induced by SI 34, a novel pyrazolo-pyrimidine derivative provided with Src inhibitory activity, the involvement of some cellular pathways that are important for cell proliferation and survival was investigated by western blot assays. In particular, the contribution of cyclins, Src and ERK were examined. Finally, experiments of cell adhesion and invasiveness were performed. Results: Treatment of SH-SY5Y human NB cells and CHP100 human neuroepithelioma (NE) cultures with three novel pyrazolo[3,4-d]pyrimidine derivatives, namely SI 34, SI 35 and SI 83, inhibits the cell proliferation in a time and concentration-dependent manner. The maximal effect was obtained after 72 hours incubation with SI 34 10 mu M. Fluorescence microscopy experiments, flow cytometry analysis and determination of caspase-3 activity by fluorimetric assays showed that SI 34 induced SH-SY5Y apoptosis. Moreover, SI 34 determined cell cycle arrest at the G0/G1 phase, paralleled by a decreased expression of cyclin D1. Furthermore, our data indicate that SI 34 reduces the SH-SY5Y cells adhesion and invasiveness. Evidence that SI 34 inhibits the Src and the ERK-phosphorylation, suggests the mechanism through which it exerts its effects in SH-SY5Y cells. Conclusions: Our study shows the ability of this pyrazolo-pyrimidine Src inhibitor in reducing the growth and the invasiveness of human NB cells, suggesting a promising role as novel drug in the treatment of neuroblastoma.
引用
收藏
页数:12
相关论文
共 39 条
  • [1] The role of Src in solid and hematologic malignancies - Development of new-generation Src inhibitors
    Alvarez, Ricardo H.
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    [J]. CANCER, 2006, 107 (08) : 1918 - 1929
  • [2] Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells
    Angelucci, Adriano
    Schenone, Silvia
    Gravina, Giovanni Luca
    Muzi, Paola
    Festuccia, Claudio
    Vicentini, Carlo
    Botta, Maurizio
    Bologna, Mauro
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (16) : 2838 - 2845
  • [3] Role of tyrosine kinase inhibitors in cancer therapy
    Arora, A
    Scholar, EM
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) : 971 - 979
  • [4] Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression
    Beppu, K
    Jaboine, J
    Merchant, MS
    Mackall, CL
    Thiele, CJ
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (01): : 46 - 55
  • [5] BJELFMAN C, 1990, CANCER RES, V50, P6908
  • [6] A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study
    Bond, Mason
    Bernstein, Mark L.
    Pappo, Alberto
    Schultz, Kirk R.
    Krailo, Mark
    Blaney, Susan M.
    Adamson, Peter C.
    [J]. PEDIATRIC BLOOD & CANCER, 2008, 50 (02) : 254 - 258
  • [7] Neuroblastoma: Biological insights into a clinical enigma
    Brodeur, GM
    [J]. NATURE REVIEWS CANCER, 2003, 3 (03) : 203 - 216
  • [8] Growth hormone receptor; mechanism of action
    Brooks, Andrew J.
    Wooh, Jong Wei
    Tunny, Kathryn A.
    Waters, Michael J.
    [J]. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2008, 40 (10) : 1984 - 1989
  • [9] Src and focal adhesion kinase as therapeutic targets in cancer
    Brunton, Valerie G.
    Frame, Margaret C.
    [J]. CURRENT OPINION IN PHARMACOLOGY, 2008, 8 (04) : 427 - 432
  • [10] Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells
    Carraro, F
    Pucci, A
    Naldini, A
    Schenone, S
    Bruno, O
    Ranise, A
    Bondavalli, F
    Brullo, C
    Fossa, P
    Menozzi, G
    Mosti, L
    Manetti, F
    Botta, M
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) : 1595 - 1598